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Purpose of the study
Co-administration of LPV/r SGC with NVP, an inducer of
CYP3A, necessitates a LPV/r dose increase. The objectives
of "The NRTI Sparing Study" were to evaluate the PK of co-
administered LPV/r and NVP in HIV-infected subjects at
week 4 and to assess any changes in these PK parameters
at 48 weeks follow-up.
Methods
In this prospective, 48-week (wk), multicentre study, 40
patients (39 ART-naive) were recruited to receive LPV/r
SGC (533/133 mg BID) plus NVP (200 mg BID) and
undergo PK sampling (0–12 hr) at wk 4 and wk 48. In one
of the two participating centres, switches to the LPV/r tab-
let formulation (400/100 mg BID) were allowed between
wk 4 and 48, once HIV-RNA was <50 copies/ml. LPV con-
centrations were determined by HPLC-MS/MS and NVP
concentrations via HPLC-UV. PK parameters were calcu-
lated via non-compartmental analysis and within-subject
changes assessed by geometric mean ratios (GMR) with
95% confidence intervals (95% CI).
Summary of results
Wk 4 PK data were available on 35 patients. Geometric
mean (95% CI) LPV AUC and C were 92012 ng.h/ml
(81237–104215) and 3979 ng/ml (3159–5011), respec-
tively. For NVP these values were 62749 ng.h/ml (55621–
70790) and 4594 ng/ml (4023–5246), respectively. At wk
24, five individuals had HIV-RNA >50 copies/ml. Wk 4 PK
data was available on 4/5 of these patients, all of whom
had LPV and NVP concentrations greater than the pro-
posed trough concentration desirable in patients with
wild-type HIV-1 (1000 and 3000 ng/ml, respectively).
Twenty-five patients also underwent wk 48 PK sampling;
of these 10 remained on SGC, while 15 switched to the
tablet formulation (400/100 mg BID). No significant
intra-individual changes in PK were observed over 48 wks
for patients remaining on SGC (p > 0.24). In those switch-
ing to the tablet, PK parameters were not significantly dif-
ferent (p > 0.68), although there was a trend towards
lower LPV C at wk 48 (see Table 1).
Conclusion
This study explored an NRTI sparing strategy. We recog-
nise that one limitation is that some patients were
switched to the LPV/r tablet formulation. The issue of
whether, if starting with this strategy, a dose of 400/100
mg or 600/150 mg tablet would be used, has not been
addressed here. PK parameters at wk 4 and 48 did not dif-
fer significantly in patients receiving co-administered
LPV/r and NVP. However, there was a trend towards lower
LPV C in patients who switched to LPV/r tablet. Therefore,
there is a need for caution and a consideration for TDM-
guided dose adjustment depending on the population.
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PK [patients remaining on LPV/r SGC (n = 10)] Wk 4 Wk 48 GMR (95% CI) CV% wk 4; wk 48
LPV AUC0–12, ng.h/ml 102951 (85318, 130692) 91589 (84050, 101101) 0.89 (0.70, 1.13) 34; 15
LPV Ctrough, ng/ml 4848 (3615, 7952) 5230 (4347, 6794) 1.08 (0.67, 1.75) 60; 35
LPV Cmax, ng/ml 12307 (10659, 14663) 11115 (10209, 12251) 0.90 (0.75, 1.08) 26; 15
NVP AUC0–12, ng.h/ml 71850 (67089, 90850) 68793 (58059, 86236) 0.96 (0.83, 1.10) 45; 33
NVP Ctrough, ng/ml 5254 (4933, 6676) 4932 (4032, 6527) 0.94 (0.76, 1.16) 45; 40
NVP Cmax, ng/ml 6924 (6440, 8741) 6830 (5846, 8385) 0.99 (0.85, 1.15) 46; 30
PK [patients switching to LPV/r tablet (n = 15)] Wk 4 Wk 48 GMR (95% CI) CV% wk 4; wk 48
LPV AUC0–12, ng.h/ml 77332 (68401, 87428) 67853 (60277, 85324) 0.88 (0.67, 1.14) 26; 34
LPV Ctrough, ng/ml 3171 (2355, 4271) 2164 (2013, 3688) 0.68 (0.37, 1.24) 62; 58
LPV Cmax, ng/ml 9393 (8619, 10518) 8706 (7618, 10846) 0.93 (0.76, 1.12) 20; 35
NVP AUC0–12, ng.h/ml 55289 (49589, 64356) 57231 (50758, 64528) 1.04 (0.88, 1.21) 26; 26
NVP Ctrough, ng/ml 3984 (3842, 4947) 4063 (3540, 4665) 1.02 (0.86, 1.21) 28; 29
NVP Cmax, ng/ml 5447 (4918, 6251) 5576 (5004, 6469) 1.02 (0.88, 1.20) 24; 25
Values given as geometric mean (95% CI); CV% = coefficient of variation (%).Page 2 of 2
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